Connections and combinations: Supporting people to help control their diabetes

Session 2

Combining efficacy and simplicity to help improve glycemic control

16:30 – 16:35Session 2 introductionJulio Rosenstock (USA)
16:35 – 16:55Simultaneous approach to therapeutic intensification: Who, when and whyYehuda Handelsman (USA)
Leigh Perreault (USA)
16:55 – 17:15Guiding personalized care with injectable therapies: Considering the needs of your patientStewart Harris (CAN)
Davida Kruger (USA)
17:15 – 17:35Advancing insulin therapy in adults with T2D: Outcomes from the SoliMix trialJulio Rosenstock (USA)
17:35 – 17:45Q&A and session summaryAll speakers

The SoliMix trial was the first randomized controlled trial to directly compare the efficacy and safety of a fixed-ratio combination of basal insulin and GLP-1 RA, iGlarLixi, with a premix insulin analog, biphasic insulin aspart 30 (30% insulin aspart and 70% insulin aspart protamine) (BIAsp 30), in people with Type 2 diabetes uncontrolled on basal insulin plus one or two oral antihyperglycemic drugs.